dialysis treatment; end-stage renal disease; type II diabetes Background. Phenacetin was removed from the German market in 1986 and was replaced mainly in analgesic compounds by acetaminophen. Our objective was to examine the effect of this measure on the
1983. Our aim was to determine the effect of phenacetin being reserved from the German market in 1986 and replaced by acetaminophen in most analgesic mixtures. In particular, we attempted to correlate the changed incidence of analgesic nephropathy and other renal diseases within the context of altered admittance policies for dialysis treatment.
Subjects and methods
We investigated the proportion of analgesic nephropathy and other renal diseases among patients starting dialysis treatment during three 18-month periods: April 1982 to September 1983, January 1991 to June 1992, and October 1995 to March 1997. The renal-disease incidences during these three periods were compared using the x2 distribution test for two random samples and additionally using the x2 distribution test for independence of different frequencies (seven renal diseases at three different time intervals). To compare the age differences during three time intervals (comparison of several independent random samples), we used the nonparametric H-test of Kruskal and Wallis, which is a generalization of Wilcoxon's rank-sum test. In cases of significant differences, multiple tests according to Tukey were performed to determine the time intervals during which the differences occurred. The ages of patients with different renal diseases are given as medians with 0.95 confidence intervals (CI 0.95 ). The diagnosis of analgesic nephropathy was based on characteristic anamnestic and clinical data [15] and, since 1991-1992, has been verified by computed tomography (CT ) scan in cases of unknown kidney disease [16 ] .
The development of the dialysis and transplant population in West Berlin was investigated by questioning all dialysis and transplant centers at different times. The age increase was significant for patients starting The x2 distribution test suggested a significant decrease dialysis treatment; but not for those with analgesic in the incidence of end-stage analgesic nephropathy: nephropathy ( Table 1 Figure 2 ). disclose a significant time dependence for the seven renal diseases (P=0.092). To compare two relative frequencies of diagnosis, an approximation based on Discussion the arcsine transformation was used. However, following the x2 test, statistically significant differences were The incidence of analgesic nephropathy must be considered within the context of its social and cultural found. The frequency of analgesic nephropathy decreased from 1982-1983 to 1996-1997 (P=0.01), background. In Germany, the period following the Second World War was characterized by tough comwhereas that of type II diabetes increased from 1982-1983 to 1991-1992 (P=0.01) and from petition to create new private and economic structures and the increasing double burden of holding a job and 1982-1983 to 1995-1997 (P=0.001) (Figure 1 ).
The incidence of other renal diseases remained household chores borne by women. This created the basis for overadaption and analgesic abuse [17, 18] . unchanged: glomerulonephritis, 18% vs 14% vs 14%, n.s.; polycystic kidney disease, 12% vs 4% vs 7%, n.s.; For some time, the correlation between analgesic abuse and interstitial nephritis was doubted [19] [20] [21] . type I diabetes, 5% vs 5% vs 3%, n.s.; various kidney diseases, 19% vs 14% vs 21%, n.s.; unclarified diagnoses, However, discussion about the nephrotoxicity of phenacetin-containing drugs was definitely ended by the 9% vs 15% vs 14%, n.s. longitudinal study of Dubach et al. [22, 23] , confirming now hardly any contraindication to chronic dialysis treatment. In addition to the resultant general increase the increased risk of renal insufficiency in patients with analgesic abuse defined by positive tests for acetamin-in patient age, type II diabetes has become the leading cause of kidney disease among the dialysis populaophen in urine. In his study, however, as in the longitudinal study of Elseviers and De Broe [24] , no tion [25, 26 ] .
Our dialysis center reflects this development. Nearly distinction was made between phenacetin-and acetaminophen-containing drugs. In Germany, after the all patients with any renal diseases are accepted for dialysis therapy. Analgesic patients have always been removal of phenacetin from analgesic mixtures in 1986, we are currently having the same discussion about among the oldest, their mean age has not changed significantly. However, the age of the other patients compound analgesics without phenacetin but often containing acetaminophen with or without another has increased considerably. Diabetic nephropathy has become the leading kidney disease, as in many other analgesic component and caffeine or codeine.
It takes years to determine the effect of changes in dialysis centers (Figure 1 ). Since the restriction of phenacetin, there have not the analgesic market on the incidence of analgesic nephropathy. Over the course of these years, there been any studies on the development of analgesic nephropathy that take into account the altered incidmay be changes in other conditions relating to the incidence of renal diseases. This has happened during ence of other renal diseases. We consider it dangerous to publish the assertion that analgesic nephropathy the last 15 years. Acceptance of older patients for dialysis, as well as those with more complicated dis-has decreased due to the restriction of phenacetin without taking into account the changing policies of eases, has increased enormously ( Figure 2 ). There is 
